Artiva Biotherapeutics recently announced that the FDA has granted Fast Track Designation to its lead candidate AlloNK for use in refractory rheumatoid...
Artiva Biotherapeutics (ARTV) Is Up 113.9% After FDA Fast Track for AlloNK in Refractory RA – Has the Bull Case Changed?
